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Diagnostic value of WT1 in neuroepithelial tumours
Abstract
Aims: Currently, clinical trials using WT1 (Wilms tumour gene) peptide vaccines are conducted in
haematopoietic malignancies and solid cancers. Single reports showed that the Wilms tumour gene
product WT1 is also expressed in astrocytic neoplasms. Our aim was to investigate WT1 expression in a
large cohort of various neuroepithelial tumours of different World Health Organization (WHO) grades
and in normal central nervous system (CNS) tissue specimens to test its potential value as a diagnostic
marker. Methods: Specimens were assessed by RT-PCR, Western blotting and immunohistochemistry.
The samples investigated in our study consisted of 334 human neuroepithelial tumours, among those 33
oligodendrogliomas, 219 astrocytomas (including 105 glioblastomas) and 47 ependymomas. Results:
Our results showed a de novo WT1 expression in neuroepithelial tumours. In diffuse astrocytomas and
ependymomas, WT1 expression increased significantly with the grade of malignancy. In contrast, no
significant difference was seen between WHO grade-II and -III oligodendrogliomas. Controlling for
WHO grade, the comparison of oligodendrogliomas with ependymal and astrocytic tumours showed
higher expression values for the latter. Conclusions: Our study shows that WT1 is expressed de novo in
numerous neuroepithelial tumours and increases with the grade of malignancy. These results suggest an
important role of WT1 in tumourigenesis and progression in human brain tumours.
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Abstract:  
(i) Aims: 
Currently, clinical trials using WT1 (Wilms tumour gene) peptide vaccines are 
conducted in haematopoietic malignancies and solid cancers. Single reports 
showed that the Wilms tumour gene product WT1 is also expressed in astrocytic 
neoplasms. Our aim was to investigate WT1 expression in a large cohort of 
various neuroepithelial tumours of different WHO grades and in normal CNS 
tissue specimens to test its potential value as a diagnostic marker. 
(ii) Methods: 
Specimens were assessed by RT-PCR, western blotting and 
immunohistochemistry. The samples investigated in our study consisted of 334 
human neuroepithelial tumours among these 33 oligodendrogliomas, 219 
astrocytomas (including 105 glioblastomas) and 47 ependymomas.  
(iii) Results: 
Our results showed a de novo WT1 expression in neuroepithelial tumours. In 
diffuse astrocytomas and ependymomas, WT1 expression increased significantly 
with the grade of malignancy. In contrast, no significant difference was seen in 
WHO grade II and III oligodendrogliomas. Controlling for WHO grade, the 
comparison of oligodendrogliomas with ependymal and astrocytic tumours 
showed higher expression values for the latter.  
(iv) Conclusions: 
In conclusion, our study shows that WT1 is expressed de novo in numerous 
neuroepithelial tumours and increases with the grade of malignancy. These 
results suggest an important role of WT1 in tumourigenesis and progression in 
human brain tumours. 
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Introduction: 
The WT1 gene encodes a zinc-finger DNA-binding protein acting as a transcription 
factor for the growth and differentiation of cells [1]. Frequent deletions of 
chromosome 11p13 regions are associated with hereditary Wilms tumour, a common 
paediatric neoplasm first reported in 1899 [2]. Alternative splicing encodes for 
different proteins of which the amino terminus was first described as a tumour 
suppressor domain [3]. Beside modulation of proliferation and apoptosis a role as 
transcriptional activator in solid tumours has been demonstrated [4]. Target genes 
include E-cadherin [5], insulin-like-growth factors IGF-I [6] and IGF-II [7] among 
others, while par-4 is a suppressor of WT1 [8]. Depending on the investigated tissue 
low WT1 expression can inhibit p53 mediated apoptosis [9], whereas high WT1 
levels result in p53-independent cell death [10]. In addition WT1 can suppress 
promoter activity of c-myc and activate bcl-2 protein [11]. Aberrant WT1 expression 
has been identified in acute leukaemia [12], desmoplastic small round cell tumour 
[13], desmoid tumours [14], rhabdomyosarcoma [15], melanoma [16], mesothelioma 
[17] and breast tumours [18]. WT1 protein plays an important role in the development 
of the retina [19], the urogenital system [20] and is also reported to be expressed in 
mammalian ependymal structures of the fourth ventricle and spinal cord [21]. In 
contrast to numerous data about WT1 expression in extracranial tumours, 
information about its expression in neuroepithelial tumours is limited to date. WT1 
expression has been reported in glioblastoma cell lines [22] and few glioma samples 
[23, 24]. Since WT1 promotes tumour cell proliferation and survival, differences in 
WT1 expression levels might influence the biological behaviour of gliomas, where 
p53 inactivation is common. In order to characterize the WT1 expression pattern, we 
investigated different human neoplastic and normal CNS tissue specimens by RT-
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PCR, western blotting and immunohistochemistry with regard to a possible 
application of WT1 as a diagnostic marker. 
 
Materials and Methods: 
Patient data 
Brain tumour samples of the present study were obtained from the tumour bank of 
the Institute of Brain Research, University of Tübingen, as previously reported [25]. 
Utilization of human specimens was in accordance with the University’s ethic 
commission. The samples included 33 oligodendrogliomas, 47 ependymomas and 
219 astrocytomas. Epidemiological data of the patients are given in Table 1. Twenty-
four autopsy cases belonging to an established normal brain bank were also included 
(14 male, 10 female, mean age: 58.6). In addition, 6 gangliogliomas, 4 central 
neurocytomas, 3 pleomorphic xanthoastrocytomas (PXA), 3 pilomyxoid astrocytomas 
(PMA), 6 medulloblastomas, 2 subependymomas, 4 subependymal giant cell 
astrocytomas (SEGA), 5 choroid plexus papillomas (CPP) and 2 dysplastic 
neuropithelial tumours (DNT) were also included in the study. Histological diagnosis 
and grading of each tumour sample was performed according to the WHO 
classification by at least two, in most cases three experienced neuropathologists [26].  
 
Tissue microarray  
Tissue microarrays were constructed by extracting cylindrical tissue core biopsies 
displaying representative tissue sections from the paraffin donor blocks followed by 
re-embedding these into a pre-punched hole on a single recipient paraffin block at 
defined array coordinates. Using this technique, previously selected tumour regions 
were extracted and prepared as a tissue microarray. A TMA machine (Beecher 
 5
Instruments, Inc., Sun Prairie; WI, USA) was used to extract a 600 µm cylindrical 
core sample from the tissue donor block. The tissue microarray blocks were then cut 
with a microtome (3µm thickness) and placed on SuperFrost Plus slides (Microm 
International, Walldorf, Germany). In total, 172 diffuse astrocytomas were arrayed on 
TMA, the remaining 23 diffuse astrocytomas and all other tumour entities as well as 
normal brains were examined using routinely cut sections.  
 
Immunohistochemistry 
Immunohistochemistry was performed on formalin-fixed paraffin-embedded tissue 
sections using a monoclonal anti-WT1 antibody, clone 6F-H2 which is directed 
against an amino-terminal located epitope of WT1 protein (dilution 1:50, Dako, 
Glostrup, Denmark). The antibody reacts with all isoforms of the full-length WT1 
protein. In addition 87 tissue specimens from 66 patients were stained with a 
polyclonal anti-WT1 antibody, clone C-19 directed against an epitope mapping at the 
C-terminus of WT1 (dilution 1:200, Santa Cruz Biotech, Santa Cruz, CA, USA) to 
validate the results. Sections were deparaffinized and immunostained using the 
Benchmark immunohistochemistry system (Ventana Medical Systems, Tucson, AZ 
USA). The automated standard protocol is based on an indirect biotin-avidin system 
and uses an universal biotinylated immunoglobulin secondary antibody and 
diaminobenzidine substrate. The sections were finally incubated with a copper 
enhancer (Ventana) and counterstained with hematoxylin. Wilms tumour or serous 
ovarial carcinoma were used as positive controls displaying a distinct nuclear staining 
pattern. Negative control slides were processed in parallel with each batch of 
staining. To obviate unspecific binding of the monoclonal antibodies, an IgG isotype 
control was performed. 
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Immunoblot 
Cell lysates were prepared in 10 mM Tris-HCl (pH 7.2) containing 50 mM NaCl, 5 µM 
ZnCl, 2mM DTT, 30, mM sodiumpyrophosphate, 1 Vol % Triton X. Protease inhibition 
was performed with the Complete Mini Inhibitor, EDTA-free system (Roche, 
Mannheim, Germany). Normalized aliquots lysates were subjected to electrophoresis 
on a 12% SDS-PAGE gel under reducing conditions and transferred to nitrocellulose 
(Schleicher & Schuell, Dassel, Germany). The lysates were assessed at 20 µg of 
total protein per lane. Equal protein loading was ascertained by Ponceau S staining 
and detection of GAPDH. After blocking nonspecific-binding sites with 5% (w/v) dried 
milk in PBS for 30 min, the filters were incubated with specific primary antibodies 
overnight at 4°C, washed and incubated with horseradish peroxidase-conjugated, 
goat anti-mouse IgG or goat anti-rabbit IgG (diluted 1 : 5000) (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) for 3 h at 22°C. The primary antibodies mouse 
anti-GAPDH (Santa Cruz Biotechnology; sc-2005; 1:1000), monoclonal mouse anti-
WT1 (DAKO; m3561; 1:500) and polyclonal rabbit anti-WT1 (Santa Cruz 
Biotechnology; sc-192; C19; 1:500), were used at 1 µg/ml in PBS containing 0.05% 
Tween 20 and 5% skim milk. Novex-Sharp (LC5800; Invitrogen, Karlsruhe, Germany) 
was used as ladder. Protein bands were visualized using enhanced 
chemiluminescence (Amersham, Braunschweig, Germany). 
 
RT-PCR 
Total RNA was isolated using the RNeasy kit (Qiagen, Hildesheim, Germany), cDNA 
was generated using MMLV reverse transcriptase (Promega) according to the 
manufacturers instructions and amplification for WT1 and beta-actin was carried out 
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using standard protocols The condition for all polymerase chain reactions were 35 
cycles of 95°C for 30 s and 59°C for 45 s. The following primers were used: WT1 (5'-
GGG CAT GTG TAT GTG TCT GC-3' and 5'- CCT GCT TTC CAG GTT AGC AG-3', 
yielding a product of 150 bp), beta-actin (5'- AGA AAA TCT GGC ACC ACA CC-3' 
and 5'- AAC GGC AGA AGA GAG AAC CA-3', yielding a product of 209 bp). 
Polymerase chain reactions were performed on an Eppendorf Thermocycler 
(Eppendorf, Hamburg, Germany) with a Taq polymerase (Promega) according to the 
manufacturer's instructions. 
 
Evaluation and Statistics: For immunohistochemistry, only samples showing WT1 
expression in endothelial cells (internal control) were scored. WT1-positive 
parenchymal cells in tumours were evaluated using a semiquantitative score with 0 
(no staining), 1 (singular positive cells, <1%), 2 (2-19%), 3 (20-50%) and 4 (>50%) 
assessed independently by three investigators. Only if two or more scores were 
identical for the same case, this score was taken into account. Additional 
neuroepithelial neoplasms which were not statistically analyzed were only divided in 
tumours showing immunopositive neoplastic cells or not, without applying the scoring 
system. Ordinal logistic regression was performed for each comparison followed by a 
likelihood ratio Chi-square test. Bonferroni-Holm correction was applied for multiple 
testing. JMP 7.0 was used for statistical analysis. (* p>0.05, ** p>0.01, *** p>0.001). 
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Results: 
WT1 expression in normal brain is restricted to endothelial cells 
In gray and white matter of 24 normal human brain samples WT1 immunoreactivity 
was restricted to endothelial cells which served as internal controls in all specimens 
investigated. Regions examined beside cortical samples included hippocampus, 
thalamus, pallidum, putamen, mesencephalon, cerebellum, pons and medulla 
oblongata. In all samples examined no neuronal or glial WT1 expression was found. 
Thus, WT1 expression in normal human brain is limited to endothelial cells (Figure 1).  
 
WT1 is expressed de novo in all investigated neuroepithelial tumour cell lineages and 
increases with malignancy. 
A varying number of diffuse astrocytomas showed a strong cytoplasmic staining 
including delicate cell processes (Figure 1). Nuclear WT1 staining was only observed 
in single tumour cells of a very small number of glioblastomas. Strong WT1 
immunoreactivity was present in pseudopalisading tumour cells around necrosis, 
possibly also including WT1 in macrophages/microglia. Except for a thin endothelial 
layer of WT1 positive cells on the luminal side, proliferating vessels were 
immunonegative for WT1. Most anaplastic astrocytomas exhibited diffusely spread 
out WT1 positive cells showing a slight preponderance of tumour cells with increased 
anaplasia intermingled with immunonegative cells. In diffuse astrocytomas, 19 out of 
36 WHO grade II (52.7%) showed at least partial expression of WT1, while 45 out of 
54 WHO grade III astrocytomas (83.3%) and 103 out of 105 glioblastomas (98.0%) 
expressed WT1 (Figure 2; Table 2). For all tumour grades in astrocytomas, WT1 
expression differed significantly from normal brain (corresponding p-values are 
shown in Table 3). Surprisingly, WT1 expression pattern in oligodendroglial tumour 
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cells was different compared to astrocytomas. The majority of low-grade 
oligodendrogliomas remained immunonegative for WT1 protein (16/24 of grade II 
WHO and 4/9 of grade III WHO). In the cases of WT1-positive oligodendrogliomas 
the positive cells invariably reflected so called minigemistocytic cells (Figure 3). In 
8/24 low-grade oligodendrogliomas and 5/9 anaplastic oligodendrogliomas no more 
than single WT1-positive tumour cells were observed resulting in no higher scores 
than 2 for this group (Table 2). The likelihood ratio Chi-square test showed no 
significant differences between grade II to III, although both tumour entities are still 
different from normal brain (Table 3). Diffuse WT1 expression was also observed in 
ependymomas (Figure 4). Most ependymal tumours showed increased WT1 
expression in cell processes radiating towards blood vessels. In ependymomas, 10 
out of 24 WHO grade II (41.7%) and 8 out of 9 WHO grade III tumours (88.9%) 
expressed WT1 in the cytoplasm (Table 2 and 3). In addition both tumour grades 
differed significantly from normal brain. 
 
Trend for higher WT1 expression levels in astrocytomas and ependymomas  
compared to oligodendrogliomas. 
 
The distribution of the WT1-scores clearly shows a shift from lower to higher scores 
with increased malignancy. Statistical comparison of WT1 expression in different 
tumours of grade II WHO showed a certain trend for higher expression in 
astrocytomas and ependymomas compared to oligodendrogliomas, but did not reach  
significance after correction for multiple testing (Table 4). In anaplastic astrocytomas 
and ependymomas several tumours were classified as score 3 and 4 (above 20% of 
positive cells). This was never observed in oligodendrogliomas (maximum score 2).  
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Although the expression levels of anaplastic astrocytomas and anaplastic 
ependymomas were higher than in low-grade oligodendrogliomas, they did not reach 
level of significance after correction for multiple testing (Table 4).    
 
Expression of WT1 is confirmed on mRNA and protein level 
 
To control for the specificity of WT1 immunohistochemistry, we additionally analyzed 
its expression in a series of 87 glioblastoma specimens using a different polyclonal 
antibody directed against a C-terminal epitope. Apart from slight unspecific 
background staining, we observed similar expression patterns including the general 
endothelial presence of WT1 protein (Figure 5A). Among the 87 evaluated samples 
15 (17.2%) were classified as score 4, 26 samples (29.9 %) score 3, 25 samples 
(28.7%) score 2 and 13 samples (14.9%) score 1, while 8 samples (9.2%) did not 
exhibit WT1 expression in tumour cells. Thus, the use of a second antibody 
confirmed WT1 expression in glial neoplasms.  
In addition, WT1 protein was detected by Western blot analysis performed on 
exemplary protein extracts from 9 astrocytic tumours, 4 oligodendrogliomas, 2 normal 
brain controls as well as 2 Wilms tumours serving as positive controls. Equal protein 
loading was assessed by the detection of GAPDH (Figure 5B). WT1 protein levels in 
normal brain tissues were quite similar to tumours displaying score 0 levels. In many 
glial neoplasms, the protein amount detected in Western blots correlated closely to 
the WT1 scores of the immunohistochemical evaluation. 
Reverse transcription PCR using a primer pair at position 2088 and 2217 of the WT1 
mRNA yielded a product of the expected size of 150 bp (Figure 5C) in several 
astrocytomas. These tumours had an immunohistochemical WT1 score of 2 and 
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higher. The expression was heterogeneous with some tumour samples showing 
slightly increased and others reduced WT1 mRNA levels compared to the 
immunohistochemical score. With the exception of a single glioblastoma sample, all 
WT1 tumours that did not display clear detectable mRNA levels had been scored 0 or 
1 (i.e. less than one percent positive tumour cells). WT1 mRNA expression in 
astrocytomas and ependymomas was increased compared to low-grade 
oligodendroglial tumours. 
 
 
WT1 expression patterns in various brain tumours is dependent on the tumour entity. 
An overview of additionally examined neuroepithelial tumours is given in Table 1 and 
2. In pilomyxoid astrocytomas and pleomorphic xanthoastrocytomas  numerous 
tumour cells expressed WT1 (Figures 6A+B). WT1 positive glial tumour cells with 
astrocytic morphology were observed in 4/6 gangliogliomas (Figure 6C). Expression 
of WT1 in all central neurocytomas (including two extraventricular located cases; 
Figure 6D) and in choroid plexus papillomas (Figure 6E) examined was restricted 
to endothelial cells, as seen in most oligodendroglial tumours and normal brain 
tissue. Both subependymomas (n=2) investigated contained some WT1 positive 
tumour cells (Figure 6F). In all subependymal giant cell tumours several to 
numerous tumour cells were WT1-positive (Figure 6G)  
In myxopapillary ependymomas and in pilocytic astrocytomas frequent WT1 
expression was observed (Figures 6H+I). In one of two dysembryoplastic 
neuroepithelial tumours numerous process-bearing cells expressed WT1 while 
oligodendroglia-like clear cells and neuronal cells showed no immunoreactivity 
(Figure 6J). Three out of six medulloblastomas exhibited focal WT1 
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immunoreactivity, especially within the centre of rosette formations. One of these 
cases showed more than 50% of immunoreactive cells (Figure 6K).   
 
 
Discussion: 
Our study shows an abundant cytoplasmic de novo expression of WT1 in neoplastic 
glial cells of human astrocytomas and ependymomas. Expression levels clearly 
increase with the grade of malignancy. This suggests that the WT1 gene might be 
involved in malignant transformation of these tumours. For some neoplasms, high 
levels of WT1 expression have been shown to correlate with a worse prognosis [12]. 
Expression of WT1 has been reported in 55-63% of malignant glioma cell lines 
examined [22, 27], while RT-PCR analysis showed WT1 mRNA in up to 88% of 
glioblastoma tumour samples [27]. Other studies using paraffin embedded tissue 
specimens reported even higher numbers of WT1–positive glioblastomas [24, 28]. 
Since data on WT1 expression in low-grade astrocytomas was limited, we included a 
large series of low grade neoplasms and could provide evidence for WT1 expression 
in 67% pilocytic astrocytomas and 52.7% WHO grade II astrocytomas. Oji and 
colleagues reported immunohistochemical WT1 expression in 5/6 WHO grade I and II 
astrocytomas [24] and similar results with RT-PCR were observed by Clark et al [27]. 
We were able to demonstrate that WT1 expression in oligodendroglial tumour cells is 
mainly attributable to minigemistocytic tumour cells. Our observations seem to be in 
contrast to the results by Hashiba and colleagues, who reported on the expression of 
WT1 in oligodendroglial tumours. A thorough search of the tissue used by Hashiba 
reveals that 7 of the 8 tumours listed as oligodendrogliomas were in fact mixed oligo-
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astrocytomas [29]. Thus, the majority of WT1 expression in these cases might result 
from astrocytic tumour cells.  
We have found the different staining pattern in astrocytomas and oligodendrogliomas 
to be helpful for the sometimes challenging distinction of these entities [30]. To date, 
no single immunohistochemical marker allows a clear differentiation between 
astrocytoma and oligodendroglioma, although expression patterns of the 
microtubule-associated-protein (MAP2) can be helpful in establishing a diagnosis 
[31]. OLIG2, initially proposed as a specific marker for oligodendrogliomas [32] is 
also expressed in other glial tumours [33]. Therefore we have adopted WT1 as an 
additional marker in our panel of antibodies employed for the assessment of gliomas 
as to date the majority of oligodendrogliomas are either immunonegative or express 
WT1 only in single cells (<1%, score 1). All oligodendrogliomas that were scored 2 
(2-19% positive cells) had a WT1 expressing “minigemistocytic” component. These 
cells are readily identifiable in HE stains and their true glial precursor is still under 
debate [34]. As a strong WT1 expression is observed in the majority of 
glioblastomas, analysis of WT1 expression might help the pathologist to differentiate 
between anaplastic oligodendroglioma and glioblastoma. In addition, the observed 
distribution pattern of WT1 could help with the difficult distinction between single and 
mixed lineage tumours, especially high-grade oligoastrocytomas, since the 
oligodendroglial part will mainly remain immunonegative in contrast to the often 
strongly positive astrocytic tumour cells. 
WT1 expression in ependymomas has recently been reported  [29]. Interestingly, a 
transient WT1 upregulation in ependymal cells of brain and spinal cord during 
embryogenesis has been described, pointing at the possibility that ependymoma 
cells might reactivate properties of ependymal precursor cells [21, 35]. The different 
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expression pattern of ependymomas (positive cell processes radiating towards 
vessels) and oligodendrogliomas (mostly negative with single positive 
minigemistocytes) may help to differentiate small endoscopic biopsies as they are 
often seen in children operated on periventricular lesions.  
 
Although WT1 in Wilms tumour and malignant mesothelioma is predominantly 
located in the nucleus [36] other solid neoplasms such as breast cancer [37], 
malignant melanoma [17], rhabdomyosarcoma [15], uterine sarcomas [38], colorectal 
cancer [39] and endometrial stromal neoplasms [40] frequently show cytoplasmic 
expression of WT1. The presence of WT1 in neoplastic cells has been confirmed 
independently in several studies by western blot [39, 41]. It has been further reported 
that WT1 protein is able to shuttle from the nucleus to the cytoplasm [42]. In line with 
our observations Nakahara et al. [28] reported a predominantly cytoplasmic WT1 
expression in glioblastomas. The consistent expression of WT1 in blood vessels has 
been noted previously [17] and a link to vascular endothelial growth factor (VEGF) 
has been established [43, 44]. Since WT1 protein levels in Western blots of normal 
brain tissues were similar to tumours displaying score 0 levels, one has to assume 
that this faint signal might be due to the residual endothelial expression. However it is 
noteworthy that in our observations WT1 expression in proliferating endothelial 
vessels of glioblastomas remains restricted to the luminal part of the endothelium, 
suggesting that WT1 is not directly involved in glioma vessel angiogenesis. 
 
Although de novo expression of WT1 in the cytoplasm of glial tumour cells seems to 
be an ideal target for immunotherapy [45-48], the consistent WT1 expression in 
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normal endothelial cells of the brain poses a risk for targeted WT1 anticancer therapy 
in brain tumours. 
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Figure legends  
Figure 1: WT1 expression patterns in diffuse astrocytomas: (A) Glioblastoma, 
WHO grade IV, (B) anaplastic astrocytoma, WHO grade III, (C) fibrillary, (D) 
protoplasmatic and (E) another fibrillary astrocytoma, all WHO grade II compared to 
(F) normal brain.  (A, B, E, F original magnification: x100, C, D: x200). 
 
Figure 2: Statistical analysis of WT1 expression in diffuse astrocytomas: 
Distribution of WT1 scores of WHO grade II (n=36) and III (n=54) astrocytomas as 
well as WHO grade IV glioblastomas (n=105) are displayed. Corresponding p-values 
are shown in table 3. 
 
Figure 3: WT1 expression patterns in oligodendrogliomas: Examples of WT1-
negative oligodendroglioma WHO grade II (A) and anaplastic oligodendroglioma 
WHO grade III (B), with positive endothelial vessels serving as internal control. (C) 
WT1 in oligodendrogliomas is only expressed in cases showing so called „mini-
gemistocytic” cells (A, B: Original magnification x200, C: x100, inset in C: x600). 
 
Figure 4: WT1 expression patterns in ependymomas: Anaplastic ependymoma 
WHO grade III (A), ependymoma WHO grade II (B), including clear cell (C) and 
tanycytic (D) variant. (A-D: OM x100). 
 
Figure 5: Confirmation of WT1 expression by A) immunohistochemistry with a 
second, polyclonal antibody directed against a different epitope of the WT1 protein in 
three exemplary glioblastoma samples (left: score 3, middle and right: score 4). B) 
immunoblot: WT1 protein amounts in glial neoplasms. WT1 protein (upper row) was 
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detected by Western blot analysis in protein extracts from 9 astrocytic, 4 
oligodendroglial and 2 normal brain specimens as well as 2 Wilms tumour specimens 
serving as positive control. Protein loading was assessed by evaluation of GAPDH 
(lower row). C) RT-PCR results show a variable WT1 expression roughly correlating 
with the immunohistochemistry score of the tumour (product size 150bp, Wilms 
tumour as positive control in lane 2, OD = oligodendroglioma, A = astrocytoma, E = 
ependymoma, GBM = glioblastoma). 
 
Figure 6: WT1 expression in other neuroepithelial tumours. Exemplary WT1 
expression patterns of (A) pilomyxoid astrocytoma (B) pleomorphic 
xanthoastrocytoma, (C) anaplastic ganglioglioma, (D) central neurocytoma, (E) 
choroid plexus papilloma, (F) subependymoma, (G) subependymal giant cell 
astrocytoma (H) myxopapillary ependymoma, (I) pilocytic astrocytoma, (J)  
dysembryoplastic neuroepithelial tumour and (K) medulloblastoma. Ovarial 
carcinoma (L) displaying a distinct nuclear staining pattern served as positive control. 
(OM: E, H, J: x100, A-D, F-G, I, K-L x200). 
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Table 1: Summary of tissue specimens 
Tumor type WHO grade Male/female Mean age No of tumours 
Pilocytic astrocytoma I 14/10 21.8 24 
Diffuse astrocytoma II 24/12 44.0 36 
Anaplastic astrocytoma III 36/18 50.1 54 
Glioblastoma IV 63/42 58.3 105 
Myxopapillary ependymoma I 11/3 33.6 14 
Ependymoma II 11/13 44.9 24 
Anaplastic ependymoma III 5/4 43.9 9 
Oligodendroglioma II 13/11 47.1 24 
Anaplastic oligodendroglioma III 3/6 46.3 9 
Pilomyxoid astrocytoma II 2/1 19.6 3 
Ganglioglioma I-III 3/3 33.7 6 
DNT I 1/1 11.0 2 
Central neurocytoma II 2/2 31.0 4 
Pleomorphic xanthoastrocytoma II 2/1 31.4 3 
Subependymoma I 2/0 58.5 2 
Medulloblastoma IV 3/3 8.3 6 
SEGA I 2/2 32.7 4 
Choroid plexus papilloma I 3/2 29.8 5 
DNT: dysembryoplastic neuroepithelial tumour; SEGA: subependymal giant cell astrocytoma 
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Table 2: WT1 immunoreactivity in CNS neoplasms 
Tumor type WT+  tumours Score 1 Score 2 Score 3 Score 4
Pilocytic astrocytoma (I) 16/24 6 7 3 0 
Diffuse astrocytoma (II) 19/36 7 8 4 0 
Anaplastic astrocytoma (III) 45/54 13 15 12 5 
Glioblastoma (IV) 103/105 8 29 37 29 
Myxopapillary ependymoma (I) 6/14 1 3 1 1 
Ependymoma (II) 10/24 7 3 0 0 
Anaplastic ependymoma (III) 8/9 1 2 4 1 
Oligodendroglioma (II) 8/24 8 0 0 0 
Anaplastic oligodendroglioma (III) 5/9 3 2 0 0 
Pilomyxoid astrocytoma (II) 2/3 
Ganglioglioma (I-III) 4/6 
DNT (I) 1/2 
Central neurocytoma (II) 0/4 
Pleomorphic xanthoastrocytoma (II) 3/3 
Subependymoma (I) 1/2 
Medulloblastoma (IV) 3/6 
SEGA (I) 4/4 
Choroid plexus papilloma (I) 0/5  
DNT: dysembryoplastic neuroepithelial tumour; SEGA: subependymal giant cell astrocytoma 
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Table 3: Comparison of WT1 expression assessed by ordinal logistic regression 
LEVEL A LEVEL B p-Value 
Pilocytic astrocytoma I Normal brain <0.0001*** 
Astrocytoma II Pilocytic astrocytoma I 0.36 (n.s.) 
Anaplastic astrocytoma III Pilocytic astrocytoma I 0.04 (#) 
Pilocytic astrocytoma I Glioblastoma IV <0.0001*** 
Glioblastoma IV Normal brain <0.0001*** 
Glioblastoma IV Astrocytoma II <0.0001*** 
Anaplastic astrocytoma III Normal brain <0.0001*** 
Glioblastoma IV Anaplastic astrocytoma III <0.0001*** 
Astrocytoma II Normal brain <0,0001*** 
Anaplastic astrocytoma III Astrocytoma II 0,001** 
   
Anaplastic oligodendroglioma III Normal brain <0.0001*** 
Oligodendroglioma II Normal brain <0,0003** 
Anaplastic oligodendroglioma III Oligodendroglioma II 0.08 (n.s.) 
   
Anaplastic ependymoma III Normal brain <0.0001*** 
Anaplastic ependymoma III Ependymoma II <0.0001*** 
Ependymoma II Normal brain <0.0001*** 
Myxopapillary ependymoma I Normal brain <0.0002** 
Ependymoma II Myxopapillary ependymoma I 0.57 (n.s.) 
Anaplastic ependymoma III Myxopapillary ependymoma I 0.0196 (#) 
n.s.: not significant; #: not significant after correction for multiple testing 
Table 4: Comparison of WT1 expression in different tumours of a certain WHO grade 
assessed by ordinal logistic regression  
#: not significant after correction for multiple testing 
LEVEL A LEVEL B p-Value 
Pilocytic astrocytoma WHO I Myxopapillary ependymoma WHO I 0.382 
Astrocytoma WHO II Ependymoma WHO II 0.250 
Astrocytoma WHO II Oligodendroglioma WHO II 0.045#
Oligodendroglioma WHO II Ependymoma WHO II 0.351 
Astrocytoma WHO III Ependymoma WHO III 0.223 
Astrocytoma WHO III Oligodendroglioma WHO III 0.038#
Oligodendroglioma WHO III Ependymoma WHO III 0.009#
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